Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRS-344/S095012 in Solid Tumors
2023-510046-25-00Phase 2Completed
- Sponsor
- Servier
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, open-label trial of PRS-344 in Nonhematologic neoplasms, Cervical Cancer (CC) and cutaneous squamous cell carcinoma (cSCC) (4 arms), sponsored by Servier. Primary endpoints: Incidence of dose-limiting toxicities (DLTs), Incidence and severity of adverse events (AEs) and 4 more. Started Jun 2024; status: completed.
02
Drugs
PRS-344
03
Conditions
Nonhematologic neoplasmsCervical Cancer (CC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2023-510046-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510046-25-00.